by Denkstrom
All storiesNew CAR-T cells eliminate brain tumor in mice

New CAR-T cells eliminate brain tumor in mice

A study published on October 28, 2026, shows that genetically engineered, brain-specific CAR-T cells eliminated diffuse midline gliomas, a deadly childhood brain tumor, in mice. They also extended the animals' survival. A trial that could begin in 2027 is intended to determine whether the cells also work safely in humans.

The study was published in Science Translational Medicine. A single infusion of the so-called B-SYNC cells was sufficient to infiltrate the tumor, persist over time and show antitumor activity in immunodeficient DMG models.

What makes diffuse midline gliomas so dangerous

Diffuse midline gliomas most commonly develop in the brainstem and predominantly affect children between 5 and 10 years old, according to a review in the Journal of Neuro-Oncology. Under the classification used by the U.S. National Cancer Institute, a tumor with an H3 K27 alteration is classified as WHO grade 4 among pediatric high-grade gliomas, whose prognosis the institute generally describes as poor. According to the review, surgical removal is not possible for anatomical reasons, and conventional chemotherapy had provided no benefit because of the intact blood-brain barrier. As of the review's publication on December 29, 2025, radiation therapy remained the only standard treatment, temporarily relieving symptoms and extending overall survival by about 3 months.

How B-SYNC cells distinguish between the brain and the body

According to the study authors, successful CAR-T-cell therapy requires both better tumor infiltration and persistence of T cells and a reduction in the risk of side effects outside the tumor. For B-SYNC, they coupled a brain-specific synthetic Notch receptor that recognizes brevican to the production of a CAR targeting EphA2 or IL-13Rα2, thereby restricting CAR expression to the central nervous system. According to the study, the platform builds on a brain-restricted CAR-T system previously tested in glioblastoma, which the researchers further developed for the anatomical and biological characteristics of diffuse midline glioma. The research group had already demonstrated the same basic principle in a study published in Science on December 6, 2024: In that study, T cells directed at the central nervous system eliminated primary and secondary brain tumors without damaging cross-reactive cells outside the brain, after the researchers had identified brain-specific antigens and developed synthetic Notch receptors that stimulate T cells to produce different therapeutic agents only in the brain.

Successes and a fatal setback in animal experiments

In the new experiments, a murinized version of the circuit targeting B7-H3 achieved durable tumor elimination and resistance to tumor recurrence in an immunocompetent mouse model with both intravenous and intracerebroventricular administration, without detectable neurotoxicity. According to The Medicine Maker, an alternative version of the circuit targeting B7-H3 and IL-13Rα2 caused fatal neurotoxicity when administered directly into the brain's ventricles, despite eliminating the tumors. Mechanistically, the synNotch-activated CAR-T cells showed less exhaustion and greater enrichment of naive and stem cell memory-like subsets. Hideho Okada, a professor of neurological surgery at the University of California, San Francisco, is a co-corresponding author of the study. According to Technology Networks, he said it had been difficult to develop CAR-T cells that could overcome diffuse midline gliomas without unacceptable side effects.

A comparison: Another CAR-T therapy has already been tested in patients

In the clinical trial of GD2-CAR-T cells, one patient's complete response lasted more than 30 months from enrollment in the trial. However, at the higher intravenous dose level, three of eight patients experienced dose-limiting grade 4 cytokine release syndrome with a drop in blood pressure or lung failure, leading to the lower dose being designated the maximum tolerated dose. As STAT reported in November 2024, Michelle Monje-Deisseroth had begun this trial in 2020 after previously having little new to offer against a tumor that, according to the report, most children did not survive for even a year. One of the patients treated, 20-year-old Drew, remained in complete remission 30 months after treatment, according to the report.

What still needs to be established before use in patients

The authors of the B-SYNC study themselves describe brain tissue-sensitive synNotch-CAR-T circuits as a transferable strategy against several malignancies of the central nervous system. According to a report dated November 3, 2026, the researchers have yet to establish whether B-SYNC is safe and effective in humans. According to SciTechDaily, the researchers are preparing an initial B-SYNC trial at UCSF Health that could begin in April 2027, in which the T cells of each participating child or young adult are to be individually converted into B-SYNC-CAR-T cells. The trial, led by UCSF physicians Marie Jaeger-Krause and Sabine Mueller, is intended to test different combinations of intravenous and intracerebroventricular administration; according to the report, an implanted shunt with a reservoir beneath the scalp is planned for repeated infusions into the brain.